Summary

Persistence Market Research has recently released a comprehensive report on the global Oral Solid Dosage Contract Manufacturing Market, offering an in-depth assessment of key market dynamics, including growth drivers, emerging trends, opportunities, and restraints. The report delivers a detailed view of the evolving market landscape, enabling pharmaceutical stakeholders, CDMOs, and investors to make informed strategic decisions.

Key Insights:

• Oral Solid Dosage Contract Manufacturing Market Size (2025E): US$ 38.0 Bn
• Projected Market Value (2032F): US$ 57.9 Bn
• Global Market Growth Rate (CAGR 2025 to 2032): 6.2%

Oral Solid Dosage Contract Manufacturing Market – Report Scope:

The oral solid dosage contract manufacturing market includes outsourced manufacturing services for solid pharmaceutical dosage forms such as tablets, capsules, softgels, powders, and granules. These services span across formulation development, scale-up, commercial manufacturing, packaging, and labeling. Oral solid dosage forms remain the most preferred route of drug administration due to their stability, ease of handling, patient compliance, and cost-effectiveness. The growing trend among pharmaceutical and biopharmaceutical companies to outsource manufacturing operations, coupled with increasing drug approvals and lifecycle management strategies, is significantly driving market growth. Advancements in modified-release technologies, high-potency drug manufacturing, and regulatory-compliant facilities further strengthen the market outlook during the forecast period.

Market Growth Drivers:

The growth of the global oral solid dosage contract manufacturing market is primarily driven by the rising outsourcing trend among pharmaceutical and biopharmaceutical companies seeking cost optimization and operational efficiency. Increasing drug development activities, particularly for generic drugs and complex formulations, have accelerated the demand for specialized contract manufacturing organizations with advanced capabilities. The expanding geriatric population and the growing prevalence of chronic diseases have led to higher consumption of oral solid dosage forms, further supporting market expansion. Additionally, the need for faster time-to-market, stringent regulatory requirements, and limited in-house manufacturing capacities are encouraging companies to rely on experienced contract manufacturers, thereby fueling sustained market growth.

Market Restraints:

Despite robust growth prospects, the oral solid dosage contract manufacturing market faces several challenges that may hinder its expansion. Strict regulatory compliance requirements across different regions increase operational complexity and cost for contract manufacturers. Dependence on pharmaceutical sponsors for long-term contracts can lead to revenue volatility, especially in cases of project delays or cancellations. Furthermore, rising competition among contract manufacturing organizations has resulted in pricing pressure, affecting profit margins. Capacity constraints and challenges related to technology transfer and quality assurance may also limit the growth potential for smaller and mid-sized players.

Market Opportunities:

The oral solid dosage contract manufacturing market presents significant opportunities driven by the increasing demand for complex and value-added dosage forms such as controlled-release and delayed-release formulations. The rapid growth of emerging and virtual pharmaceutical companies, which heavily depend on outsourcing partners, creates substantial opportunities for contract manufacturers. Expansion into nutraceutical and gummy dosage manufacturing is opening new revenue streams. Moreover, growing pharmaceutical production in emerging regions such as South Asia, East Asia, and Latin America, along with investments in advanced manufacturing technologies and continuous manufacturing processes, is expected to unlock long-term growth opportunities for market participants.

Competitive Analysis:

Key players operating in the global oral solid dosage contract manufacturing market include:

• Recipharm
• Aenova Holding
• Catalent
• AbbVie
• Patheon N.V. (Thermo Fisher Scientific)
• NextPharma
• Lonza Group AG
• Merck KGaA
• Aurobindo Pharma Limited
• Siegfried AG
• Piramal Pharma Solutions
• Corden Pharma
• HERMES PHARMA GmbH
• Medipaams India Private Limited
• Alpex Pharma
• Abaris Healthcare Pvt Ltd
• Ardena Holdings N.V
• Aphena Pharma Solutions
• Actiza Pharmaceutical Private Limited
• Sunwin Healthcare PVT. LTD
• Kosher Pharmaceuticals
• Boehringer Ingelheim BioXcellence

Oral Solid Dosage Contract Manufacturing Market Segmentation

By Dosage Form:

• Tablets
• Capsules
• Softgels
• Powders
• Granules
• Gummies
• Others

By Mechanism:

• Immediate Release
• Delayed Release
• Controlled Release

By Application:

• Drug Product Development
• Fill & Finish Product Manufacturing
• Packaging / Labelling
• Others

By End User:

• Pharmaceutical Companies
• Biopharmaceutical Companies
• Emerging/Virtual Pharma Companies
• Nutraceutical Companies

By Region:

• North America
• Europe
• East Asia
• South Asia and Oceania
• Middle East and Africa
• Latin America

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Oral Solid Dosage Contract Manufacturing Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025 - 2032, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Regulatory Landscape
3.2. Product Adoption Analysis
3.3. Value Chain Analysis
3.4. Key Deals and Mergers
3.5. PESTLE Analysis
3.6. Porter’s Five Force Analysis
4. Global Oral Solid Dosage Contract Manufacturing Market Outlook:
4.1. Key Highlights
4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
4.2.2. Market Size (US$ Bn) Analysis and Forecast, 2025-2032
4.3. Global Oral Solid Dosage Contract Manufacturing Market Outlook: Dosage Form
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Bn) Analysis, By Dosage Form, 2019 - 2024
4.3.3. Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2025 - 2032
4.3.3.1. Tablets
4.3.3.2. Capsules
4.3.3.3. Softgels
4.3.3.4. Powders
4.3.3.5. Granules
4.3.3.6. Gummies
4.3.3.7. Others
4.3.4. Market Attractiveness Analysis: Dosage Form
4.4. Global Oral Solid Dosage Contract Manufacturing Market Outlook: Mechanism
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Bn) Analysis, By Mechanism, 2019 - 2024
4.4.3. Market Size (US$ Bn) Analysis and Forecast, By Mechanism, 2025 - 2032
4.4.3.1. Immediate Release
4.4.3.2. Delayed Release
4.4.3.3. Controlled Release
4.4.4. Market Attractiveness Analysis: Mechanism
4.5. Global Oral Solid Dosage Contract Manufacturing Market Outlook: Application
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019 - 2024
4.5.3. Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
4.5.3.1. Drug Product Development
4.5.3.2. Fill & Finish Product Manufacturing
4.5.3.3. Packaging /Labelling
4.5.3.4. Others
4.5.4. Market Attractiveness Analysis: Application
4.6. Global Oral Solid Dosage Contract Manufacturing Market Outlook: End User
4.6.1. Introduction / Key Findings
4.6.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019 - 2024
4.6.3. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
4.6.3.1. Pharmaceutical Companies
4.6.3.2. Biopharmaceutical Companies
4.6.3.3. Emerging/Virtual Pharma Companies
4.6.3.4. Nutraceutical Companies
4.6.4. Market Attractiveness Analysis: End User
5. Global Oral Solid Dosage Contract Manufacturing Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2024
5.3. Market Size (US$ Bn) Analysis and Forecast, By Region, 2025 - 2032
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Oral Solid Dosage Contract Manufacturing Market Outlook:
6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
6.2.1. By Country
6.2.2. By Dosage Form
6.2.3. By Mechanism
6.2.4. By Application
6.2.5. By End User
6.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
6.3.1. U.S.
6.3.2. Canada
6.4. Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2025 - 2032
6.4.1. Tablets
6.4.2. Capsules
6.4.3. Softgels
6.4.4. Powders
6.4.5. Granules
6.4.6. Gummies
6.4.7. Others
6.5. Market Size (US$ Bn) Analysis and Forecast, By Mechanism, 2025 - 2032
6.5.1. Immediate Release
6.5.2. Delayed Release
6.5.3. Controlled Release
6.6. Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
6.6.1. Drug Product Development
6.6.2. Fill & Finish Product Manufacturing
6.6.3. Packaging /Labelling
6.6.4. Others
6.7. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
6.7.1. Pharmaceutical Companies
6.7.2. Biopharmaceutical Companies
6.7.3. Emerging/Virtual Pharma Companies
6.7.4. Nutraceutical Companies
6.8. Market Attractiveness Analysis
7. Europe Oral Solid Dosage Contract Manufacturing Market Outlook:
7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
7.2.1. By Country
7.2.2. By Dosage Form
7.2.3. By Mechanism
7.2.4. By Application
7.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkey
7.3.8. Rest of Europe
7.4. Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2025 - 2032
7.4.1. Tablets
7.4.2. Capsules
7.4.3. Softgels
7.4.4. Powders
7.4.5. Granules
7.4.6. Gummies
7.4.7. Others
7.5. Market Size (US$ Bn) Analysis and Forecast, By Mechanism, 2025 - 2032
7.5.1. Immediate Release
7.5.2. Delayed Release
7.5.3. Controlled Release
7.6. Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
7.6.1. Drug Product Development
7.6.2. Fill & Finish Product Manufacturing
7.6.3. Packaging /Labelling
7.6.4. Others
7.7. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
7.7.1. Pharmaceutical Companies
7.7.2. Biopharmaceutical Companies
7.7.3. Emerging/Virtual Pharma Companies
7.7.4. Nutraceutical Companies
7.8. Market Attractiveness Analysis
8. East Asia Oral Solid Dosage Contract Manufacturing Market Outlook:
8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
8.2.1. By Country
8.2.2. By Dosage Form
8.2.3. By Mechanism
8.2.4. By Application
8.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2025 - 2032
8.4.1. Tablets
8.4.2. Capsules
8.4.3. Softgels
8.4.4. Powders
8.4.5. Granules
8.4.6. Gummies
8.4.7. Others
8.5. Market Size (US$ Bn) Analysis and Forecast, By Mechanism, 2025 - 2032
8.5.1. Immediate Release
8.5.2. Delayed Release
8.5.3. Controlled Release
8.6. Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
8.6.1. Drug Product Development
8.6.2. Fill & Finish Product Manufacturing
8.6.3. Packaging /Labelling
8.6.4. Others
8.7. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
8.7.1. Pharmaceutical Companies
8.7.2. Biopharmaceutical Companies
8.7.3. Emerging/Virtual Pharma Companies
8.7.4. Nutraceutical Companies
8.8. Market Attractiveness Analysis
9. South Asia & Oceania Oral Solid Dosage Contract Manufacturing Market Outlook:
9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
9.2.1. By Country
9.2.2. By Dosage Form
9.2.3. By Mechanism
9.2.4. By Application
9.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2025 - 2032
9.4.1. Tablets
9.4.2. Capsules
9.4.3. Softgels
9.4.4. Powders
9.4.5. Granules
9.4.6. Gummies
9.4.7. Others
9.5. Market Size (US$ Bn) Analysis and Forecast, By Mechanism, 2025 - 2032
9.5.1. Immediate Release
9.5.2. Delayed Release
9.5.3. Controlled Release
9.6. Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
9.6.1. Drug Product Development
9.6.2. Fill & Finish Product Manufacturing
9.6.3. Packaging /Labelling
9.6.4. Others
9.7. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
9.7.1. Pharmaceutical Companies
9.7.2. Biopharmaceutical Companies
9.7.3. Emerging/Virtual Pharma Companies
9.7.4. Nutraceutical Companies
9.8. Market Attractiveness Analysis
10. Latin America Oral Solid Dosage Contract Manufacturing Market Outlook:
10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
10.2.1. By Country
10.2.2. By Dosage Form
10.2.3. By Mechanism
10.2.4. By Application
10.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2025 - 2032
10.4.1. Tablets
10.4.2. Capsules
10.4.3. Softgels
10.4.4. Powders
10.4.5. Granules
10.4.6. Gummies
10.4.7. Others
10.5. Market Size (US$ Bn) Analysis and Forecast, By Mechanism, 2025 - 2032
10.5.1. Immediate Release
10.5.2. Delayed Release
10.5.3. Controlled Release
10.6. Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
10.6.1. Drug Product Development
10.6.2. Fill & Finish Product Manufacturing
10.6.3. Packaging /Labelling
10.6.4. Others
10.7. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
10.7.1. Pharmaceutical Companies
10.7.2. Biopharmaceutical Companies
10.7.3. Emerging/Virtual Pharma Companies
10.7.4. Nutraceutical Companies
10.8. Market Attractiveness Analysis
11. Middle East & Africa Oral Solid Dosage Contract Manufacturing Market Outlook:
11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
11.2.1. By Country
11.2.2. By Dosage Form
11.2.3. By Mechanism
11.2.4. By Application
11.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2025 - 2032
11.4.1. Tablets
11.4.2. Capsules
11.4.3. Softgels
11.4.4. Powders
11.4.5. Granules
11.4.6. Gummies
11.4.7. Others
11.5. Market Size (US$ Bn) Analysis and Forecast, By Mechanism, 2025 - 2032
11.5.1. Immediate Release
11.5.2. Delayed Release
11.5.3. Controlled Release
11.6. Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
11.6.1. Drug Product Development
11.6.2. Fill & Finish Product Manufacturing
11.6.3. Packaging /Labelling
11.6.4. Others
11.7. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025 - 2032
11.7.1. Pharmaceutical Companies
11.7.2. Biopharmaceutical Companies
11.7.3. Emerging/Virtual Pharma Companies
11.7.4. Nutraceutical Companies
11.8. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2024
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Recipharm
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Aenova Holding
12.3.3. Catalent
12.3.4. AbbVie
12.3.5. Patheon N.V. (Thermo Fisher Scientific)
12.3.6. NextPharma
12.3.7. Lonza Group AG
12.3.8. Merck KGaA
12.3.9. Aurobindo Pharma Limited
12.3.10. Siegfried AG
12.3.11. Piramal Pharma Solutions
12.3.12. Corden Pharma
12.3.13. HERMES PHARMA GmbH
12.3.14. Medipaams India Private Limited
12.3.15. Alpex Pharma
12.3.16. Abaris Healthcare Pvt Ltd
12.3.17. Ardena Holdings N.V
12.3.18. Aphena Pharma Solutions
12.3.19. Actiza Pharmaceutical Private Limited
12.3.20. Sunwin Healthcare PVT. LTD
12.3.21. Kosher Pharmaceuticals
12.3.22. Boehringer Ingelheim BioXcellence
12.3.23. Others
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations